Zenas BioPharma (ZBIO) Other Non Operating Income (2023 - 2026)

Zenas BioPharma's Other Non Operating Income history runs 4 years deep, the most recent figure standing at -$24000.0 for Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 115.19% year-over-year to -$24000.0 in Q1 2026; TTM through Mar 2026 was $7.2 million, a 6541.96% increase from a year earlier, with the FY2025 full-year figure at $10.8 million, up 5242.08% from the prior year.
• Other Non Operating Income eased to -$24000.0 in Q1 2026 per ZBIO's latest filing, from $3.2 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $3.2 million in Q4 2025 and bottomed at -$4.5 million in Q4 2024.
• The 4-year median for Other Non Operating Income is $793000.0 (2023), against an average of $759272.7.
• Biggest YoY gain for Other Non Operating Income was 14962.5% in 2024; the steepest drop was 670.62% in 2024.
• Year by year, Other Non Operating Income stood at $793000.0 in 2023, then plunged by 670.62% to -$4.5 million in 2024, then soared by 170.67% to $3.2 million in 2025, then slumped by 100.75% to -$24000.0 in 2026.
• Per Business Quant, the three latest ZBIO Other Non Operating Income figures stand at -$24000.0 (Q1 2026), $3.2 million (Q4 2025), and $1.1 million (Q3 2025).